Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase

Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu

Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Chiba University Japan.

Oxidative metabolic pathways of propranolol consist of naphthalene ring- hydroxylations (at the 4-, 5-, and 7-positions) and side-chain N- desisopropylation in mammals. We characterized cytochrome P450 isozymes responsible for propranolol metabolism, especially N-desisopropylation and 5-hydroxylation, in human liver microsomes. 4-Hydroxy, 5-hydroxy-, and N-desisopropylpropranolol were detected as primary metabolites, whereas 7-hydroxypropranolol was in trace amounts. Good correlations were obtained for activities of propranolol 4- and 5-hydroxylases with immunochemically determined CYP2D6 content, whereas correlations of these activities with CYP1A2, CYP2C, or CYP3A4 content were relatively low. The activities also correlated highly with debrisoquine 4- hydroxylase, compared with other metabolic activities such as phenacetin O-deethylase, hexobarbital 3'-hydroxylase, and testosterone 6 beta-hydroxylase, which are typical reactions for CYP1A2, CYP2C, and CYP3A4, respectively. Propranolol N-desisopropylase activity in the samples highly correlated with CYP1A2 content and phenacetin O- deethylase activity, but not with the other P450 isozyme contents or metabolic activities. Quinidine, a specific inhibitor of CYP2D6, inhibited propranolol 4- and 5-hydroxylase activities selectively and in a concentration-dependent manner. alpha-Naphthoflavone, a potent inhibitor of CYP1A2, inhibited all of the propranolol oxidation activities, and the IC50 value for N-desisopropylase activity was much smaller than the values for ring-hydroxylase activities. Antibody directed to CYP2D inhibited propranolol 4- and 5-hydroxylase activities by 70% at an antibody/microsomal protein ratio of 1.0. Anti-CYP2C9 antibody did not inhibit any activity determined. These results indicate that propranolol 5-hydroxylation, as well as 4-hydroxylation, is mainly catalyzed by CYP2D6 in human liver microsomes.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 22, Issue 6, pp. 909-915, 11/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. P. Gibbs, R. Hyland, and K. Youdim Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism Drug Metab. Dispos., September 1, 2006; 34(9): 1516 - 1522. [Abstract] [Full Text] [PDF]

				D. Y. Hung, G. A. Siebert, P. Chang, M. W. Whitehouse, L. Fletcher, D. H. G. Crawford, and M. S. Roberts Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G343 - G351. [Abstract] [Full Text] [PDF]

				Y. Masubuchi and T. Horie ENDOTOXIN-MEDIATED DISTURBANCE OF HEPATIC CYTOCHROME P450 FUNCTION AND DEVELOPMENT OF ENDOTOXIN TOLERANCE IN THE RAT MODEL OF DEXTRAN SULFATE SODIUM-INDUCED EXPERIMENTAL COLITIS Drug Metab. Dispos., April 1, 2004; 32(4): 437 - 441. [Abstract] [Full Text] [PDF]

				P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR Drug Metab. Dispos., November 1, 2003; 31(11): 1352 - 1360. [Abstract] [Full Text] [PDF]

				T. Hiroi, T. Chow, S. Imaoka, and Y. Funae Catalytic Specificity of CYP2D Isoforms in Rat and Human Drug Metab. Dispos., September 1, 2002; 30(9): 970 - 976. [Abstract] [Full Text] [PDF]

				A. L. Upthagrove and W. L. Nelson Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propranolol Derivatives. Preparation, Identification of Metabolite Regioisomers, and Metabolism by CYP2D6 Drug Metab. Dispos., November 1, 2001; 29(11): 1377 - 1388. [Abstract] [Full Text] [PDF]

				A. L. Upthagrove and W. L. Nelson Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propranolol Analogs: Metabolism by CYP1A2 Drug Metab. Dispos., November 1, 2001; 29(11): 1389 - 1395. [Abstract] [Full Text] [PDF]

				C. Y. Ng, H. Ghabrial, D. J. Morgan, M. S. Ching, R. A. Smallwood, and P. W. Angus Impaired Elimination of Propranolol Due to Right Heart Failure: Drug Clearance in the Isolated Liver and Its Relationship to Intrinsic Metabolic Capacity Drug Metab. Dispos., October 1, 2000; 28(10): 1217 - 1221. [Abstract] [Full Text] [PDF]

				J. A. Johnson, V. L. Herring, M. S. Wolfe, and M. V. Relling CYP1A2 and CYP2D6 4-Hydroxylate Propranolol and Both Reactions Exhibit Racial Differences J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1099 - 1105. [Abstract] [Full Text]

				D. C. Mankowski The Role of CYP2C19 in the Metabolism of (+/-) Bufuralol, the Prototypic Substrate of CYP2D6 Drug Metab. Dispos., September 1, 1999; 27(9): 1024 - 1028. [Abstract] [Full Text]

				Y. Masubuchi and T. Horie Dihydralazine-Induced Inactivation of Cytochrome P450 Enzymes in Rat Liver Microsomes Drug Metab. Dispos., April 1, 1998; 26(4): 338 - 342. [Abstract] [Full Text]